Publications
Analytical Validity
-
Nikiforova MN, Lepe M, Tolino LA, Miller ME, Ohori NP, Wald AI, Landau MS, Kaya C, Malapelle U, Bellevicine C, Troncone G, Nikiforov YE, Baloch Z. Thyroid Cytology Smear Slides: An Untapped Resource for ThyroSeq Testing. Cancer Cytopathol. 2020. doi: 10.1002/cncy.22331
-
Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana dos Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE. Analytical Performance of the ThyroSeq v3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules. Cancer. 2018 Apr 15;124(8):1682-1690. doi:10.1002/cncr.31245
-
Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq ) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60. doi: 10.1210/jc.2013-2292.
Clinical Validity
- Skaugen JM, Taneja C, Liu JB, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology [published online ahead of print, 2022 Sep 1]. Thyroid. 2022;10.1089/thy.2022.0282. doi:10.1089/thy.2022.0282
- Gallant JN, Chen SC, Ortega CA, Rohde SL, Belcher RH, Netterville JL, Baregamian N, Wang H, Liang J, Ye F, Nikiforov YE, Nikiforova MN, Weiss VL. Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children. JAMA Oncol. 2022 Jun 9:e221655. doi: 10.1001/jamaoncol.2022.1655.
-
Doerfler WR, Nikitski AV, Morariu EM, et al. Molecular alterations in Hürthle cell nodules and preoperative cancer risk. Endocr Relat Cancer. 2021;28(5):301-309. Published 2021 Apr 27. doi:10.1530/ERC-20-0435
-
Morariu, Elena M et al. “Clinicopathologic Characteristics of Thyroid Nodules Positive for the THADA-IGF2BP3 Fusion on Preoperative Molecular Analysis.” Thyroid : official journal of the American Thyroid Association vol. 31,8 (2021): 1212-1218. doi:10.1089/thy.2020.0589
-
Nikiforov YE, Baloch ZW. Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology. Cancer Cytopathol. 2019 Feb; doi: 10.1002/cncy.22112
-
Nikiforova MN, Nikitski AV, Panebianco F, Kaya C, Yip L, Williams MD, Chiosea SI, Seethala R, Roy S, Condello V, Santana-Santos L, Wald AI, Carty SE, Ferris RL, El-Naggar AK, Nikiforov YE. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid. 2019 Jan; doi.org/10.1089/thy.2018.0791
-
Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2018 Nov; doi:10.1001/jamaoncol.2018.4616
-
Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, Hallanger-Johnson JE, Otto KJ, Rogers KD, Centeno BA, McIver B. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer. 2017 Mar;24(3):127-136. doi: 10.1530/ERC-16-0512.
-
Shrestha RT, Evasovich MR, Amin K, Radulescu A, Sanghvi TS, Nelson AC, Shahi M, Burmeister LA. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience. Thyroid. 2016 Aug;26(8):1068-76. doi: 10.1089/thy.2016.0048.
-
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.
-
Smith R, Ferris R. Utility of Diagnostic Molecular Markers for Evaluation of Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2016 May 1; 142(5): 421–422.
-
Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid. 2015 25:1217-23.
-
Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014; 120(23):3627-34.
Clinical Utility
- Liu JB, Ramonell KM, Carty SE, et al. Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes [published online ahead of print, 2022 Oct 19]. Surgery. 2022;S0039-6060(22)00723-1. doi:10.1016/j.surg.2022.05.048
- Hescot S, Al Ghuzlan A, Henry T, et al. Prognostic of recurrence and survival in poorly differentiated thyroid cancer. Endocr Relat Cancer. 2022;29(11):625-634. Published 2022 Sep 30. doi:10.1530/ERC-22-0151
-
McCrary HC, Aoki J, Huang Y, et al. Mutation based approaches to the treatment of anaplastic thyroid cancer [published online ahead of print, 2022 Jan 24]. Clin Endocrinol (Oxf). 2022;10.1111/cen.14679. doi:10.1111/cen.14679
-
Figge JJ, Gooding WE, Steward DL, et al. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?. Thyroid. 2021;31(11):1673-1682. doi:10.1089/thy.2021.0119
-
Li W, et al. The utility of ThyroSeq ® in the management of indeterminate thyroid nodules by fine-needle aspiration. Cytopathology. 2021 Apr 29. doi: 10.1111/cyt.12981.
-
Hier J, et al. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review. J of Otolaryn – Head & Neck Surg. 2021. doi: 10.1186/s40463-021-00500-6.
-
Yip L, Gooding WE, Nikitski A, Wald AI, Carty SE, Karslioglu-French E, Seethala RR, Zandberg DP, Ferris RL, Nikiforova MN, Nikiforov YE. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case‐control study. Cancer. 2021. doi: 10.1002/cncr.33421.
-
Orloff LA. ThyroSeq v3 in the Real World: A Wide Variety of Molecular Signatures Are Recognized, with a High Benign Call Rate for Indeterminate Thyroid Nodules. Clin Thyroidol. 2020;32(12):567-569. doi: 10.1089/ct.2020;32.567-569.
-
Livhits MJ, Zhu CY, Kuo EJ, Nguyen DT, Kim J, Tseng C, Leung AM, Rao J, Levin M, Douek ML, Beckett KR, Cheung DS, Gofnung YA, Smooke-Praw S, Yeh MW. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec; doi: 10.1001/jamaoncol.2020.5935.
-
Desai D, Lepe M, Baloch ZW, Mandel SJ. ThyroSeq v3 for Bethesda III and IV: An Institutional Experience. Cancer Cytopathol. 2020. doi: 10.1002/cncy.22362
-
Carty SE, Ohori NP, Hilko DA, McCoy KL, French EK, Manroa P, Morariu E, Sridharan S, Seethala RR, Yip L. The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Ann Surg. 2020;272(4):621-627. doi: 10.1097/SLA.0000000000004130.
-
Abdelhakam DA, Mojica RE, Huenerberg KA, Nassar A. Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience. JASC. 2020. doi: 10.1016/j.jasc.2020.09.005.
-
Chen T, Gilfix BM, Rivera J, Sadeghi N, Richardson K, Hier MP, Forest VI, Fishman D, Caglar D, Pusztaszeri M, Mitmaker EJ, Payne RJ. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting. Thyroid. 2020. doi: 10.1089/thy.2019.0539.
-
Chin PD, Zhu CY, Sajed DP, Fishbein GA, Yeh MW, Leung AM, Livhits MJ. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules. Endocr Pathol. 2020. doi: 10.1007/s12022-020-09641-2.
-
Jug R, Foo W, Jones C, Ahmadi S, Jiang S. High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution. Cancer Cytopathol. 2020;128(8):563-569. doi: 10.1002/cncy.22283.
-
Guan H, Toraldo G, Cerda S, Godley FA, Rao SR, McAneny D, Doherty G, Braverman L, Lee SL. Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort. Thyroid. 2020;30(4):536-547. doi: 10.1089/thy.2019.0116.
- Ohori NP, Landau MS, Manroa P, Schoedel KE, Seethala RR. Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses. JASC. 2020;9(4):213-220. doi: 10.1016/j.jasc.2020.03.004.
-
Spaulding SL, Ho R, Everest S, Chai RL. The role of molecular testing in the diagnosis of medullary thyroid cancer: A case report of oncocytic medullary thyroid carcinoma and review of the literature. Am J Otolaryngol. 2019;11:102312.
-
Malik N, Nikitski AV, Klam E, Hunt J, Witt B, Chadwick B, Nikiforov YE, and Abraham D. Molecular Profile and Clinical Outcomes in Differentiated Thyroid Cancer Patients Presenting with Bone Metastasis. Endocr Pract. 2019. doi: 10.4158/EP-2019-0265.
-
Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Diagn Cytopathol. 2019;47(10):977-985. doi: 10.1002/dc.24247.
-
Jug R, Parajuli S, Ahmadi S, Jiang XS. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules. Endocr Pathol. 2019 Mar. doi: 10.1007/s12022-019-9571-x.
-
Borowczyk M, Szczepanek-Parulska E, Olejarz M, Więckowska B, Verburg FA, Dębicki S, Budny B, Janicka-Jedyńska M, Ziemnicka K, Ruchała M. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. Endocr Pathol. 2018 Dec; https://doi.org/10.1007/s12022-018-9560-5
-
Ohori NP, Landau MS, Carty SE, Yip L, LeBeau SO, Manroa P, Seethala RR, Schoedel KE, Nikiforova MN, Nikiforov YE. Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathol. 2018 Dec; doi: 10.1002/cncy.22088
-
Pearlstein S, Lahouti AH, Opher E, Nikiforov YE, and Kuriloff DB. Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of Hürthle Cell Neoplasms. 2018 Jul; doi: 10.1155/2018/9329035.
-
Taye A, Gurciullo D, Miles BA, Gupta A, Owen RP, Inabnet WB, Beyda JN, Marti JL. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery 2018 Jan;163(1):97-103. doi: 10.1016/j.surg.2017.07.032.
-
Cho M, Oweity T, Brandler TC, Fried K. and Levine P. Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: A correlation of clinical data, ancillary studies, and molecular analysis. Cancer Cytopathology 2017 Sep; 125: 674–682.
-
Patel SG, Carty SE, McCoy KL, Ohori NP, LeBeau SO, Seethala RR, Nikiforova MN, Nikiforov YE, Yip L. Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery. 2017 Jan;161(1):168-175.
-
Picarsic JL, Buryk MA, Ozolek J, Ranganathan S, Monaco SE, Simons JP, Witchel SF, Gurtunca N, Joyce J, Zhong S, Nikiforova MN, Nikiforov YE. Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. Pediatr Dev Pathol. 2016;19(2):115-22. doi: 10.2350/15-07-1667-OA.1.
-
Khatami R, Heimann A, Hwang S, Shroyer K, Wu M. ThyroSeq v2 Application Study for Indeterminate Thyroid FNAs with Surgical Follow-up; Experience at a University Hospital. Am J Clin Pathol 2016;146:SA54.
-
Shrestha RT, Karunamurthy A, Amin K, Nikiforov YE, Caramori ML. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report. Thyroid. 2015 Dec;25(12):1375-8. doi: 10.1089/thy.2015.0278.
-
Yip L, Wharry LI, Armstrong MJ, Silbermann A, McCoy KL, Stang MT, Ohori NP, LeBeau SO, Coyne C, Nikiforova MN, Bauman JE, Johnson JT, Tublin ME, Hodak SP, Nikiforov YE, Carty SE. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg. Jul 2014; 260(1):163-168.
-
Nikiforova MN, Nikiforov YE. Molecular genetics and the diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.
Cost-Effectiveness
-
Nicholson KJ, Roberts MS, McCoy KL, Carty SE, Yip L. Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid. 2019 Sep;29(9):1237-1243. doi: 10.1089/thy.2018.0779.
-
Rivas AM, Nassar A, Zhang J, Casler JD, Chindris AM, Smallridge R, Bernet V. ThyroSeq V2.0 Molecular Testing: A Cost-Effective Approach for the Evalulation of Indeterminate Thyroid Nodules. Endocr Pract. 2018 Sept; 24(9):780-788.
-
Yip L, Apfel A, Singhi A, Yoo J, McCoy K, Stang M, Ohori P, LeBeau S, Nikiforova M, Wisniewski S, Carty S, Nikiforov Y. Comprehensive cost analysis of available molecular tests for thyroid nodules with follicular neoplasm cytology. 15th International Thyroid Congress. 2015; A-381s.